# Dxcover Cancer Liquid Biopsy

Source: https://onco.cc/drugs/dxcover-cancer-liquid-biopsy/  
OnCo record `dxcover-cancer-liquid-biopsy` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Glasgow company's blood test that shines infrared light through serum to look for cancer; it is sold in the UK for brain tumours, and the multi-cancer version is still in study.

## Summary

In Dxcover's discovery study (Cameron et al., British Journal of Cancer 2023; 2,092 patients, eight cancers) areas under the curve against symptomatic controls ranged from 0.76 (breast) to 0.91 (colorectal, kidney, lung), and pooling all eight against asymptomatic controls the model detected 64% of stage I cancers at 99% specificity, with 57% overall sensitivity. The company's AACR 2026 release claims more than 90% sensitivity for stage I to IV colorectal, pancreatic and ovarian cancer, without sample size or specificity.

Dxcover describes the technology as a platform for multiple cancers with a first application in brain tumours: its brain test is UKCA-marked and available in the UK to registered GPs and private specialists (company, 13 February 2026), supported by the EMBRACE study (Brennan et al., ESMO Open 2026; 86% sensitivity for brain cancer). Dxcover announced CE-IVDR Class C certification on 3 March 2026 without naming the product or indication in the release. No FDA status or price was found.

## Fields

- Kind: Treatment
- Status: emerging
- Last checked: 2026-10-29
- Also known as: PANAROMIC; Dxcover spectroscopic liquid biopsy
- Tags: test; mced; evidence:insufficient
- Brand: Dxcover
- Modality: Multi-cancer blood test (infrared spectroscopy of serum)
- Mechanism: Fourier transform infrared spectroscopy of a drop of dried serum captures the overall chemical make-up of the blood; machine learning separates cancer from no cancer.

## Notes

- Evidence grade insufficient for the claim that taking this test reduces late-stage diagnosis or cancer deaths: no randomised trial of it has reported either outcome, and its published performance comes from case-control or single-arm studies. The only randomised result for any multi-cancer test, NHS-Galleri, did not show fewer stage III or IV cancers.
- The multi-cancer figures are from a discovery study; the product sold in the UK is the brain tumour test.
- What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening).

## Sources

- Cameron et al., British Journal of Cancer 2023: https://doi.org/10.1038/s41416-023-02423-7
- Brennan et al., ESMO Open 2026 (EMBRACE, brain): https://doi.org/10.1016/j.esmoop.2025.105938
- Dxcover: CE-IVDR certification (3 March 2026): https://www.dxcover.com/post/dxcover-secures-ce-ivdr-certification/

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- companies: [Dxcover](https://onco.cc/companies/dxcover/)
- key papers: [A spectroscopic liquid biopsy for the earlier detection of multiple cancer types](https://onco.cc/key-papers/paper-dxcover-spectroscopy-bjc-2023/)

---
JSON: https://onco.cc/api/v1/entities/dxcover-cancer-liquid-biopsy.json